Journal article icon

Journal article

The future of myelodysplastic syndrome—patient priorities and outcomes that matter

Abstract:
BackgroundWithout a definitive curative option available to many patients, learning to live with myelodysplastic syndrome (MDS) and manage symptoms effectively becomes a priority in their care. Anaemia is an almost universal feature of MDS. Individuals suffer differently and better individualisation of care is needed. Most MDS patient information offers scant appreciation for disease heterogeneity, variable response to treatment and each patient’s likely trajectory.MethodsWe undertook a two-part, online workshop to discuss what matters most to people living with MDS. Patients generated questions about their condition which they felt should be addressed by research or change how their care is delivered. Patients voted on the importance of each topic, creating a “prioritised” list of issues.ResultsFourteen participants of varying age and experience took part raising 56 unique questions under the themes of: prognosis; end of life; treatment; supportive care; medical staff training; diagnosis and communication. These reflect the symptoms of MDS, improving quality of life (QoL) and communication.DiscussionAlthough haemoglobin (Hb) levels have correlation to QoL, it is widely reported that other factors are important in determining QoL and need for transfusions varies despite stable Hb levels. We showed that Hb level and the need for transfusions is not comparable between different patients and even non-comparable over time meaning that the maximal benefit and timing of transfusions cannot be determined from Hb alone. This workshop highlighted patient dissatisfaction with the “numbers-led” approach and the need for an alternative method to determine when to transfuse
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3389/fmed.2023.1267139

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-7696-2826
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-6287-6708
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Strategic
Role:
Author
ORCID:
0000-0002-7414-4950


Publisher:
Frontiers Media
Journal:
Frontiers in Medicine More from this journal
Volume:
10
Pages:
1267139-1267139
Article number:
1267139
Publication date:
2023-12-18
DOI:
EISSN:
2296-858X
ISSN:
2296-858X


Language:
English
Keywords:
Pubs id:
1596271
Local pid:
pubs:1596271
Source identifiers:
W4389895547
Deposit date:
2026-06-04
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP